AMEX:SENS

Stock Analysis Report

Executive Summary

Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe.

Rewards

Revenue is forecast to grow 47.37% per year

Risk Analysis

Earnings are forecast to decline by an average of -14.7% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has Senseonics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SENS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.9%

SENS

-0.4%

US Medical Equipment

0.7%

US Market


1 Year Return

-67.6%

SENS

21.5%

US Medical Equipment

18.2%

US Market

Return vs Industry: SENS underperformed the US Medical Equipment industry which returned 21.5% over the past year.

Return vs Market: SENS underperformed the US Market which returned 18.2% over the past year.


Shareholder returns

SENSIndustryMarket
7 Day-2.9%-0.4%0.7%
30 Day-12.5%3.4%1.5%
90 Day-14.1%4.5%5.0%
1 Year-67.6%-67.6%22.6%21.5%20.8%18.2%
3 Year-67.2%-67.2%89.0%83.4%45.2%35.8%
5 Yearn/a124.0%99.6%71.6%52.7%

Price Volatility Vs. Market

How volatile is Senseonics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Senseonics Holdings undervalued compared to its fair value and its price relative to the market?

7.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SENS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SENS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SENS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SENS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SENS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SENS is overvalued based on its PB Ratio (7.8x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Senseonics Holdings forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-14.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SENS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SENS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SENS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SENS's revenue (47.4% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: SENS's revenue (47.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SENS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Senseonics Holdings performed over the past 5 years?

-32.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SENS is currently unprofitable.

Growing Profit Margin: SENS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SENS is unprofitable, and losses have increased over the past 5 years at a rate of -32% per year.

Accelerating Growth: Unable to compare SENS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SENS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: SENS has a negative Return on Equity (-344.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Senseonics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SENS's short term assets ($161.6M) exceed its short term liabilities ($22.0M).

Long Term Liabilities: SENS's short term assets ($161.6M) exceed its long term liabilities ($119.7M).


Debt to Equity History and Analysis

Debt Level: SENS's debt to equity ratio (356.2%) is considered high.

Reducing Debt: SENS's debt to equity ratio has increased from 98.3% to 356.2% over the past 5 years.


Balance Sheet

Inventory Level: SENS has a low level of unsold assets or inventory.

Debt Coverage by Assets: SENS's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SENS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SENS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -43% each year


Next Steps

Dividend

What is Senseonics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SENS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SENS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SENS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SENS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SENS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Senseonics Holdings's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Tim Goodnow (57yo)

4yrs

Tenure

US$2,171,443

Compensation

Dr. Timothy T. Goodnow, also known as Tim, Ph.D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD2.17M) is above average for companies of similar size in the US market ($USD1.12M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

48yo

Average Age

Experienced Management: SENS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

4.0yrs

Average Tenure

60yo

Average Age

Experienced Board: SENS's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$97,35011 Sep 19
Timothy Goodnow
EntityIndividual
Role
Chief Executive Officer
President
Shares88,500
Max PriceUS$1.10

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.6%.


Management Team

  • Jon Isaacson (48yo)

    • Tenure: 0.08yrs
  • Tim Goodnow (57yo)

    President

    • Tenure: 4yrs
    • Compensation: US$2.17m
  • Fran Kaufman (68yo)

    Chief Medical Officer & Director

    • Tenure: 0.08yrs
  • Mukul Jain (46yo)

    Chief Operating Officer

    • Tenure: 2.9yrs
    • Compensation: US$1.38m
  • Nick Tressler (46yo)

    Chief Financial Officer

    • Tenure: 0.08yrs

Board Members

  • Doug Roeder (48yo)

    Non-Management Director

    • Tenure: 4yrs
    • Compensation: US$158.73k
  • Ed Fiorentino (60yo)

    Non-Management Director

    • Tenure: 4yrs
    • Compensation: US$155.63k
  • Stephen DeFalco (57yo)

    Chairman

    • Tenure: 4yrs
    • Compensation: US$172.25k
  • Tim Goodnow (57yo)

    President

    • Tenure: 4yrs
    • Compensation: US$2.17m
  • Fran Kaufman (68yo)

    Chief Medical Officer & Director

    • Tenure: 0.08yrs
  • Michael Helmus (65yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Doug Prince (65yo)

    Non-Management Director

    • Tenure: 4yrs
    • Compensation: US$164.88k
  • Peter Klein (41yo)

    Non-Management Director

    • Tenure: 4yrs
    • Compensation: US$155.63k
  • James Anderson (78yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Pishko

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Senseonics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Senseonics Holdings, Inc.
  • Ticker: SENS
  • Exchange: AMEX
  • Founded: 1996
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$197.532m
  • Shares outstanding: 203.45m
  • Website: https://www.senseonics.com

Number of Employees


Location

  • Senseonics Holdings, Inc.
  • 20451 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SENSAMEX (NYSE MKT LLC)YesNew Common StockUSUSDDec 2015
6L6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2015

Biography

Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/10 00:21
End of Day Share Price2019/12/09 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.